Obsessive-compulsive Disorder Clinical Trial
Official title:
Ventral Capsular/Ventral Striatal Gamma Capsulotomy for Obsessive-compulsive Disorder: a Randomized Controlled Trial
Up to 40% of Obsessive-Compulsive Disorder (OCD) patients do not respond to conventional
treatments (medications or behavior therapy). For some of them, a neurosurgical treatment
can be indicated. Among various surgical techniques, Gamma Knife radiosurgery has the
advantage of not requiring the production of burr hole openings in the skull. However, there
are no randomized controlled trials of radiosurgical procedures.
The investigators' aim is to investigate whether radiosurgery for the treatment of severe
and refractory OCD is efficacious and safe, by a double-blind, randomized controlled trial.
Forty-eight refractory OCD patients will be randomized into two different groups: the first
one will receive standard radiosurgery; the second group will be submitted to a false
radiosurgery ("sham operation"). Patients who had been previously submitted to sham surgery
will be able to undergo real operations after one year of follow-up, when blinding is
broken. For a minimum period of one year, patients will be periodically followed-up in terms
of psychiatric changes (including OCD symptoms), global functioning, cognitive/personality
changes and neuroimaging findings.
Various studies have demonstrated that good treatment responses in Obsessive Compulsive
Disorder (OCD) are often obtained in 60 to 80 % of patients, whether employing serotonin
reuptake inhibitors or behavior therapy. However, a subgroup of OCD patients are refractory
to the classical therapeutic options, even after maximum dosage regimens and sufficiently
long treatment follow-ups are devised. Severe psychosocial and occupational impairments are
meanwhile observable. These subjects are often referred to stereotactic neurosurgeries.
Among the various surgical techniques, a radiosurgical modality (double-shot ventral
capsular/ventral striatal - VC/VS gamma capsulotomy, or simply double-shot gamma ventral
capsulotomy) has been recently developed. On the other hand, there are no randomized
controlled trials of Gamma Knife radiosurgeries in Psychiatry.
The aim of this study is to investigate whether double-shot VC/VS gamma capsulotomy is
efficacious and to describe its adverse events/complications profiles, in a double-blind,
randomized controlled trial of this radiosurgical technique for the treatment of refractory
OCD.
Forty-eight refractory OCD patients will be randomized into two different groups: the first
one will receive standard radiosurgery; the second group will be submitted to a false
radiosurgical intervention ("sham operation"). All subjects will be previously assessed by a
preliminary clinical/psychiatric interview, as well as by extensive specific instruments
regarding psychiatric diagnosis, OCD evolution and severity, anxiety/depression symptoms,
tics expression, psychosocial impairment, personality changes, etc. A neuropsychological
tests battery will also be employed. All patients will be offered a periodical follow-up,
during which assessment scales and neuroimaging exams (magnetic resonance imaging) will be
repeated. Patients who had been previously submitted to placebo surgery will be able to
undergo real operations after the one-year follow-up period, when blinding is broken. Scores
results will be analyzed among the groups, as well as adverse events profiles,
cognitive/personality changes, clinical global functioning and neuroimaging findings.
Improvements in Yale-Brown Obsessive Compulsive Scale (YBOCS) and Clinical Global Impression
(CGI) scores will be taken as the primary treatment response criteria.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04934007 -
Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder
|
N/A | |
Recruiting |
NCT04071990 -
Family Involvement in CBGT of OCD: a Randomized Controlled Trial
|
N/A | |
Completed |
NCT02541968 -
Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder
|
N/A | |
Recruiting |
NCT05651295 -
A Precision Medicine Approach to Target Engagement for Emotion Regulation
|
N/A | |
Recruiting |
NCT05391503 -
Light Therapy for Obsessive-compulsive Disorder (OCD)
|
N/A | |
Recruiting |
NCT04539951 -
Pragmatic Trial of Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT03416504 -
Methods for Managing Intrusive Thoughts
|
N/A | |
Not yet recruiting |
NCT06029738 -
Effect on Obsessive-Compulsive Beliefs and Symptoms of MCT-OCD
|
N/A | |
Recruiting |
NCT02844049 -
European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS
|
N/A | |
Terminated |
NCT02909660 -
What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT02911324 -
Cannabinoid Medication for Adults With OCD
|
Phase 1/Phase 2 | |
Completed |
NCT02217995 -
Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients
|
N/A | |
Terminated |
NCT02234011 -
A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder
|
Phase 2 | |
Withdrawn |
NCT01953042 -
Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders
|
N/A | |
Completed |
NCT02655926 -
Deep Brain Stimulation for Severe Obsessive Compulsive Disorder
|
N/A | |
Terminated |
NCT00758966 -
Naltrexone SR and Fluoxetine Combination Therapy in Subjects With Obsessive-Compulsive Disorder
|
Phase 2 | |
Completed |
NCT00742664 -
Behavioral Treatment of Obsessive-Compulsive Symptoms in Youth With Prader-Willi Syndrome: A Pilot Project
|
Phase 1/Phase 2 | |
Completed |
NCT04919785 -
Deep Brain Stimulation in Severe Obsessive-compulsive Disorder
|
N/A | |
Completed |
NCT00523718 -
Riluzole Augmentation in Treatment-refractory Obsessive-compulsive Disorder
|
Phase 2 | |
Completed |
NCT00074815 -
Treatment of Obsessive Compulsive Disorder in Children
|
Phase 3 |